RT3 (Reta)

RT3 — Triple Receptor Agonist Research Peptide

RT3 is a next-generation research peptide engineered to simultaneously engage three metabolic receptor targets: GLP-1, GIP, and glucagon receptors. This triple agonist mechanism represents a significant advancement over single- and dual-receptor compounds in preclinical metabolic research.

Mechanism of Action

RT3 activates glucagon-like peptide-1 (GLP-1) receptors to potentiate glucose-dependent insulin secretion, glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance incretin signaling, and glucagon receptors to promote energy expenditure and lipid oxidation. The combined activation of all three pathways creates a synergistic metabolic effect studied extensively in preclinical models of obesity and insulin resistance.

Research Applications

• Metabolic pathway modulation and energy homeostasis
• Insulin sensitivity and glucose regulation studies
• Appetite signaling and food intake research
• Body composition and lipid metabolism investigations
• Comparative studies with single- and dual-receptor agonists

Product Specifications

• Quantity: Varied per vial
• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: Refrigerate after reconstitution
• Testing: USA lab tested, COA available

For research purposes only. Not for human use or consumption.